MarketScreener Strategies Genmab A/S Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
06:00:00 24/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 34.75 USD | -1.33% |
|
+1.02% | +12.82% |
| 03:07pm | Hansa Biopharma brings in two new board members | FW |
| 02:55pm | Nordic stocks in North America, Astra Zeneca fell 1.2% | FW |
MarketScreener Strategies
Search
 | Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course | 07 August 2026 at 11:12 pm AEST |
 | Genmab soars after raising its guidance | 07 August 2026 at 06:00 pm AEST |
 | Genmab rebounds on a European Commission decision | 07 July 2026 at 05:52 pm AEST |
 | Genmab: Financing weighs now, pipeline pays later | 23 June 2026 at 09:20 pm AEST |
| Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis | 09 May 2026 at 10:05 pm AEST |
| Genmab: 2025 miss and cautious 2026 targets erode investor confidence | 19 February 2026 at 01:09 am AEDT |
| Genmab advances on earnings strength and pipeline while lower valuation opens upside | 08 November 2025 at 02:01 am AEDT |
| Genmab: A bold shift from defensive to aggressive | 30 September 2025 at 12:45 am AEST |
 | Genmab: From now on, courage to the most patient | 02 April 2025 at 01:57 am AEDT |
No results match your criteria
Filters
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- News Genmab A/S
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
